Across TCGA pan-cancer cohorts, TRAV9-2 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TRAV9-2’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAV9-2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAV9-2 is over-expressed in tumor, although a few such as LUSC and COAD show the opposite, repressed pattern.
KIRC, BRCA, and LUAD are the cancer types where TRAV9-2 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRAV9-2 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.